Third Quarter 2023 Updates, 
Including Our New Mission Statement

During the third quarter, we refined our mission statement to better capture the spirit of what we endeavor to do each day here at Cumberland Pharmaceuticals. It now reads as follows:

Second Quarter 2023 Updates, Including Expanded FDA Approval for Caldolor and Publication of Newborn Clinical Study Results

In the second quarter of 2023, we advanced our business, as the operating environment continued to slowly improve from the post-pandemic challenges. Our team has been working diligently to maximize the potential of our commercial brands, progress our pipeline and pursue select acquisitions. 

First Quarter 2023 Updates, Including NOPAIN Act and FDA Fee Waiver

We have continued to successfully manage our business despite the challenges in our operating environment. Our team has remained dedicated to delivering high-quality medicines for our patients, while also developing new medicines for the future. 

Third Quarter 2022 Updates, Including New Headquarters and Sancuso® Transition

We have had another successful quarter and are working hard to finish the year strong. We’re excited to announce that we’ve moved into our new headquarters on the Broadwest campus in the Vanderbilt/West End corridor of Nashville. This move allows us to continue collaborating with Vanderbilt University Medical Center and will accommodate our anticipated growth.

Highlights from the third quarter include:

CUMBERLAND PHARMACEUTICALS MOVES INTO NEW HEADQUARTERS AT BROADWEST

NASHVILLE, Tenn., Nov. 1, 2022 – Cumberland Pharmaceuticals Inc.

First Quarter 2022 Updates, Including Our Sancuso® Acquisition and Co-promotion Partnership

At Cumberland, we’re always seeking opportunities to maximize the potential of our existing brands, develop new ways to use our products, expand our roster of distinguished partners and acquire select new brands. We're pleased to share several notable developments on this front from the first quarter of 2022:

2021 Company Highlights

2021 was full of activity at Cumberland – and we’re especially proud to share several significant developments from a year that presented its share of challenges.

Company and Product Updates

Although the COVID-19 pandemic continues to affect our lives and communities as we approach the end of 2021, we are optimistic as vaccination rates rise and case counts decline, and we remain fully operational while keeping our team safe and our facilities open.

Mid-Year Check In: COVID-19 and Product Line Updates

Though the COVID-19 pandemic endures, we at Cumberland Pharmaceuticals remain hopeful as vaccination rates continue to rise. We are carefully monitoring the situation so that we can act quickly, if necessary, to keep our employees safe and our business strong.